Clinical trials
Completed Epilepsies, Partial trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
136 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2002 | 4 |
| 2003 | 4 |
| 2004 | 12 |
| 2005 | 9 |
| 2006 | 7 |
| 2007 | 10 |
| 2008 | 12 |
| 2009 | 8 |
| 2010 | 6 |
| 2011 | 11 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 136 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| UCB Pharma | 15 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 13 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 12 |
| SK Life Science, Inc. | 12 |
| Pfizer | 8 |
| Bial - Portela C S.A. | 7 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 7 |
| GlaxoSmithKline | 5 |
| Marinus Pharmaceuticals | 3 |
| Supernus Pharmaceuticals, Inc. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Epilepsies, Partial | 136 |
| Epilepsy | 72 |
| Seizures | 45 |
| Epilepsy, Complex Partial | 9 |
| Brain Diseases | 7 |
| Epilepsy, Generalized | 7 |
| Drug Resistant Epilepsy | 3 |
| Lennox Gastaut Syndrome | 3 |
| Disease | 2 |
| Epilepsy, Partial, Motor | 2 |
Trials
Showing 76 to 100 of 136. Each trial links to its page on Pharma Observatory.
36 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.